Literature DB >> 19758683

Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.

Lisa F Newcomb1, James D Brooks, Peter R Carroll, Ziding Feng, Martin E Gleave, Peter S Nelson, Ian M Thompson, Daniel W Lin.   

Abstract

Active surveillance is a management plan for localized prostate cancer that offers selective delayed intervention on indication of disease progression, allowing patients to delay or avoid treatment and associated side-effects. Outcomes from centers that promote active surveillance are favorable, with high rates of disease-specific survival. However, there remains a need for prognostic variables or biomarkers that distinguish with high specificity the aggressive cancers that progress on surveillance from the indolent cancers. The Canary Prostate Active Surveillance Study is a multicenter study and a biorepository that will discover and confirm biomarkers of aggressive disease as defined by histologic, prostate-specific antigen, or clinical criteria. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758683      PMCID: PMC3827723          DOI: 10.1016/j.urology.2009.05.050

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  37 in total

1.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

2.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Authors:  Richard Choo; Laurence Klotz; Cyril Danjoux; Gerard C Morton; Gerrit DeBoer; Ewa Szumacher; Neil Fleshner; Peter Bunting; George Hruby
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 4.  Active surveillance with selective radical treatment for localized prostate cancer.

Authors:  Nicholas J van As; Chris C Parker
Journal:  Cancer J       Date:  2007 Sep-Oct       Impact factor: 3.360

5.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

6.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

7.  Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.

Authors:  Fei Dong; Michael W Kattan; Ewout W Steyerberg; J Stephen Jones; Andrew J Stephenson; Fritz H Schröder; Eric A Klein
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

8.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.

Authors:  W R Parulekar; M McKenzie; K N Chi; L Klotz; C Catton; M Brundage; K Ding; A Hiltz; R Meyer; F Saad
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

View more
  31 in total

Review 1.  Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Authors:  Sudhir Srivastava; Brian J Reid; Sharmistha Ghosh; Barnett S Kramer
Journal:  J Cell Physiol       Date:  2016-04-29       Impact factor: 6.384

2.  A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Authors:  M A Liss; J M Schenk; A V Faino; L F Newcomb; H Boyer; J D Brooks; P R Carroll; A Dash; M D Fabrizio; M E Gleave; P S Nelson; M L Neuhouser; J T Wei; Y Zheng; J L Wright; D W Lin; I M Thompson
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

3.  Modeling grade progression in an active surveillance study.

Authors:  Lurdes Y T Inoue; Bruce J Trock; Alan W Partin; Herbert B Carter; Ruth Etzioni
Journal:  Stat Med       Date:  2013-10-09       Impact factor: 2.373

4.  Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Authors:  James D Brooks; Wei Wei; Jonathan R Pollack; Robert B West; Jun Ho Shin; John B Sunwoo; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli
Journal:  Prostate       Date:  2016-06-21       Impact factor: 4.104

Review 5.  Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Authors:  H Ballentine Carter
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

Review 6.  Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer.

Authors:  Christopher J Welty; Matthew R Cooperberg; Peter R Carroll
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

7.  The dilemma of prostate-specific antigen testing.

Authors:  Robin Leach; Ian M Thompson
Journal:  Arch Intern Med       Date:  2012-06-11

8.  Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Authors:  M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

9.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

Authors:  Jeffrey J Tosoian; Mufaddal Mamawala; Jonathan I Epstein; Patricia Landis; Sacha Wolf; Bruce J Trock; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

10.  Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Authors:  Lisa F Newcomb; Ian M Thompson; Hilary D Boyer; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; William J Ellis; Ladan Fazli; Ziding Feng; Martin E Gleave; Priya Kunju; Raymond S Lance; Jesse K McKenney; Maxwell V Meng; Marlo M Nicolas; Martin G Sanda; Jeffry Simko; Alan So; Maria S Tretiakova; Dean A Troyer; Lawrence D True; Funda Vakar-Lopez; Jeff Virgin; Andrew A Wagner; John T Wei; Yingye Zheng; Peter S Nelson; Daniel W Lin
Journal:  J Urol       Date:  2015-08-29       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.